Sernissi Lorenzo, Trabocchi Andrea, Scarpi Dina, Bianchini Francesca, Occhiato Ernesto G
Department of Chemistry 'U. Schiff', University of Florence, Via della Lastruccia 13, I-50019 Sesto Fiorentino, Italy.
Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, I-50134 Florence, Italy.
Bioorg Med Chem. 2016 Feb 15;24(4):703-11. doi: 10.1016/j.bmc.2015.12.039. Epub 2015 Dec 24.
4-Amino- and 5-amino-cyclopropane pipecolic acids (CPAs) with cis relative stereochemistry between the carboxylic and amino groups were used as templates to prepare cyclic peptidomimetics containing the RGD sequence as possible integrin binders. The peptidomimetic c(RGD8) built on the 5-amino-CPA displayed an inhibition activity (IC50=2.4nM) toward the αvβ3 integrin receptor (expressed in M21 human melanoma cell line) comparable to that of the most potent antagonists reported so far and it was ten times more active than the corresponding antagonist c(RGD7) derived from the isomeric 4-amino-CPA. Both compounds were also nanomolar ligands of the α5β1 integrin (expressed in human erythroleukemia cell line K562). These results suggest that the CPA-derived templates are suitable for the preparation of dual αvβ3 and α5β1 ligands to suppress integrin-mediated events as well as for targeted drug delivery in cancer therapy.
具有羧基和氨基之间顺式相对立体化学的4-氨基环丙烷哌啶酸(CPA)和5-氨基环丙烷哌啶酸被用作模板,以制备含有RGD序列的环状拟肽,作为可能的整合素结合剂。基于5-氨基-CPA构建的拟肽c(RGD8)对αvβ3整合素受体(在M21人黑色素瘤细胞系中表达)显示出抑制活性(IC50=2.4nM),与迄今为止报道的最有效的拮抗剂相当,并且其活性比源自异构体4-氨基-CPA的相应拮抗剂c(RGD7)高十倍。这两种化合物也是α5β1整合素(在人红白血病细胞系K562中表达)的纳摩尔配体。这些结果表明,CPA衍生的模板适用于制备双αvβ3和α5β1配体,以抑制整合素介导的事件,以及用于癌症治疗中的靶向药物递送。